Enveric Biosciences Inc. (ENVB) — CAMBRIDGE, Mass., November 04, 2026--Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced results from a quantitative electroencephalography (qEEG) study of its lead candidate, EB-003, in mice. The study demonstrated modulation of brain activity in prefrontal and parietal regions of the cortex, providing functional evidence of central
Source: Business Wire — read the full announcement there.
Browse more sector announcements in our press release archive.